DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

Data Compilation
#PharmaFlow

Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

Stock Recap
#PipelineProspector

Glycopyrronium

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

47 API Suppliers, 23 USDMF, 9 CEP/COS, 2 JDMF, 6 EU WC, 5 KDMF, 20 NDC API, 30 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

33 Drugs in Development

33 Drugs in Development

FINISHED DOSAGE FORMULATIONS

147 FDF Dossiers, 86 FDA Orange Book, 22 Europe, 13 Canada, 1 Australia, 7 South Africa, 18 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 1MG, TABLET;ORAL - 2MG, INJECTABLE;INJECTION - 0.2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INHALATION - 15.6MCG/INH, POWDER;INHALATION - 15.6MCG/INH;27.5MCG/INH, SOLUTION;INHALATION - 25MCG/ML, TABLET, ORALLY DISINTEGRATING;ORAL - 1.7MG

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc, 6 SPI Pharma, 1 DKSH, 4 Boai NKY Pharmaceuticals Ltd, 13 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 8 Actylis, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 10 BASF, 6 DFE Pharma, 3 Finar, 5 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 27 Kerry, 12 Microlex e.U, 1 Nippon Fine Chemical, 1 Novo Excipients, 3 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 26 Roquette, 1 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

72 Fillers, Diluents & Binders, 33 Direct Compression, 20 Disintegrants & Superdisintegrants, 19 Co-Processed Excipients, 16 Granulation, 15 Thickeners and Stabilizers, 15 Parenteral, 14 Film Formers & Plasticizers, 12 Lubricants & Glidants, 11 Taste Masking, 11 Solubilizers, 10 Controlled & Modified Release, 10 Coating Systems & Additives, 7 Chewable & Orodispersible Aids, 6 Topical, 3 Emulsifying Agents, 1 Surfactant & Foaming Agents, 1 Rheology Modifiers, 1 Dry Powder Inhalation, 1 Soft Gelatin, 1 API Stability Enhancers

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 113 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 27 Finished Drug Prices, 25 Annual Reports

MARKET PLACE

23 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

32 US Patents, 4 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 5 USP, 11 Others

$ Xls download

Filters

Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
28/09/2024	Inke S.A	Spain	Samoh Pharmaceutical Co., Ltd.	20201103-211-J-782	Glycopyrronium bromide	2020-11-03	INKE SA	Spain	C/Argent 1, Area Industrial del Llobregat 08755 Castellbisbal Barcelona, Spain
28/09/2024	PCAS	France	AstraZeneca Korea Ltd.	20220908-211-J-1360	Glycopyrronium bromide	2022-09-08	PCAS Finland Oy@AstraZeneca Pharmaceuticals LP	France	Messukentankatu 8, 20210 Turku, Finland@200 Cardinal Way Redwood City, CA 94063 USA

Glycopyrronium

Glycopyrronium

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

47 API Suppliers

23 USDMF

9 CEP/COS

2 JDMF

6 EU WC

5 KDMF

20 NDC API

30 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

33 Drugs in Development

FINISHED DOSAGE FORMULATIONS

147 FDF Dossiers

86 FDA Orange Book

22 Europe

13 Canada

1 Australia

7 South Africa

18 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 1MG

TABLET;ORAL - 2MG

INJECTABLE;INJECTION - 0.2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INHALATION - 15.6MCG/INH

POWDER;INHALATION - 15.6MCG/INH;27.5MCG/INH

SOLUTION;INHALATION - 25MCG/ML

TABLET, ORALLY DISINTEGRATING;ORAL - 1.7MG

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc

6 SPI Pharma

1 DKSH

4 Boai NKY Pharmaceuticals Ltd

13 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

8 Actylis

5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

10 BASF

6 DFE Pharma

3 Finar

5 Gangwal Chemicals

1 Ideal Cures Pvt Ltd

3 Ingredion Pharma Solutions

27 Kerry

12 Microlex e.U

1 Nippon Fine Chemical

1 Novo Excipients

3 Pharmatrans-Sanaq

5 Pluviaendo

3 Prachin Chemical

26 Roquette

1 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

10 Sigachi Industries

2 Ulanqab Kema New Material

1 Valens Pharmachem

3 Vasa Pharmachem

1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

72 Fillers, Diluents & Binders

33 Direct Compression

20 Disintegrants & Superdisintegrants

19 Co-Processed Excipients

16 Granulation

15 Thickeners and Stabilizers

15 Parenteral

14 Film Formers & Plasticizers

12 Lubricants & Glidants

11 Taste Masking

11 Solubilizers

10 Controlled & Modified Release

10 Coating Systems & Additives

INJECTABLE;INJECTION - 0.2MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons